FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897046116> ?p ?o ?g. }

• W2897046116 endingPage "104" @default.
• W2897046116 startingPage "97" @default.
• W2897046116 abstract "Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma (MPA). Randomized clinical trials evaluating intensified chemotherapies including FOLFIRINOX and nab-paclitaxel plus gemcitabine (NAB+GEM) have shown improvement in survival. Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe.A retrospective multi-center study including 1056 MPA patients, between 2012 and 2015, from nine centers in UK, Germany, Italy, Hungary and the Swedish registry was performed. Follow-up was at least 12 months. Cox proportional Harzards regression was used for uni- and multivariable evaluation of prognostic factors.Of 1056 MPA patients, 1030 (98.7%) were assessable for survival analysis. Gemcitabine monotherapy was the most commonly used regimen (41.3%), compared to FOLFIRINOX (n = 204, 19.3%), NAB+GEM (n = 81, 7.7%) and other gemcitabine- or 5-FU-based regimens (n = 335, 31.7%). The median overall survival (OS) was: FOLFIRINOX 9.9 months (95%CI 8.4-12.6), NAB+GEM 7.9 months (95%CI 6.2-10.0), other combinations 8.5 months (95%CI 7.7-9.3) and gemcitabine monotherapy 4.9 months (95%CI 4.4-5.6). Compared to gemcitabine monotherapy, any combination of chemotherapeutics improved the survival with no significant difference between the intensified regimens. Multivariable analysis showed an association between treatment center, male gender, inoperability at diagnosis and performance status (ECOG 1-3) with poor prognosis.Gemcitabine monotherapy was predominantly used in 2012-2015. Intensified chemotherapy improved OS in comparison to gemcitabine monotherapy. In real-life settings, the OS rates of different treatment approaches are lower than shown in randomized phase III trials." @default.
• W2897046116 created "2018-10-26" @default.
• W2897046116 creator A5003454059 @default.
• W2897046116 creator A5014477435 @default.
• W2897046116 creator A5022836234 @default.
• W2897046116 creator A5025272654 @default.
• W2897046116 creator A5025327353 @default.
• W2897046116 creator A5036567967 @default.
• W2897046116 creator A5041062229 @default.
• W2897046116 creator A5042856380 @default.
• W2897046116 creator A5043235442 @default.
• W2897046116 creator A5043533251 @default.
• W2897046116 creator A5046638351 @default.
• W2897046116 creator A5046639573 @default.
• W2897046116 creator A5057198461 @default.
• W2897046116 creator A5058451751 @default.
• W2897046116 creator A5062126812 @default.
• W2897046116 creator A5068096506 @default.
• W2897046116 creator A5075059160 @default.
• W2897046116 creator A5077413029 @default.
• W2897046116 creator A5085191511 @default.
• W2897046116 creator A5087850177 @default.
• W2897046116 date "2019-01-01" @default.
• W2897046116 modified "2023-10-02" @default.
• W2897046116 title "Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe" @default.
• W2897046116 cites W1615726156 @default.
• W2897046116 cites W1931508686 @default.
• W2897046116 cites W1996502080 @default.
• W2897046116 cites W2016245625 @default.
• W2897046116 cites W2027389238 @default.
• W2897046116 cites W2035758159 @default.
• W2897046116 cites W2079418758 @default.
• W2897046116 cites W2082636073 @default.
• W2897046116 cites W2107780185 @default.
• W2897046116 cites W2113566724 @default.
• W2897046116 cites W2115658806 @default.
• W2897046116 cites W2117491278 @default.
• W2897046116 cites W2131764595 @default.
• W2897046116 cites W2135352785 @default.
• W2897046116 cites W2151253787 @default.
• W2897046116 cites W2158134441 @default.
• W2897046116 cites W2159140139 @default.
• W2897046116 cites W2161817637 @default.
• W2897046116 cites W2165480504 @default.
• W2897046116 cites W2309290604 @default.
• W2897046116 cites W2321177546 @default.
• W2897046116 cites W2344385257 @default.
• W2897046116 cites W2469831351 @default.
• W2897046116 cites W2539521142 @default.
• W2897046116 cites W2559800688 @default.
• W2897046116 cites W2563179702 @default.
• W2897046116 cites W2581973599 @default.
• W2897046116 cites W4211208840 @default.
• W2897046116 doi "https://doi.org/10.1016/j.pan.2018.10.003" @default.
• W2897046116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30529068" @default.
• W2897046116 hasPublicationYear "2019" @default.
• W2897046116 type Work @default.
• W2897046116 sameAs 2897046116 @default.
• W2897046116 citedByCount "32" @default.
• W2897046116 countsByYear W28970461162019 @default.
• W2897046116 countsByYear W28970461162020 @default.
• W2897046116 countsByYear W28970461162021 @default.
• W2897046116 countsByYear W28970461162022 @default.
• W2897046116 countsByYear W28970461162023 @default.
• W2897046116 crossrefType "journal-article" @default.
• W2897046116 hasAuthorship W2897046116A5003454059 @default.
• W2897046116 hasAuthorship W2897046116A5014477435 @default.
• W2897046116 hasAuthorship W2897046116A5022836234 @default.
• W2897046116 hasAuthorship W2897046116A5025272654 @default.
• W2897046116 hasAuthorship W2897046116A5025327353 @default.
• W2897046116 hasAuthorship W2897046116A5036567967 @default.
• W2897046116 hasAuthorship W2897046116A5041062229 @default.
• W2897046116 hasAuthorship W2897046116A5042856380 @default.
• W2897046116 hasAuthorship W2897046116A5043235442 @default.
• W2897046116 hasAuthorship W2897046116A5043533251 @default.
• W2897046116 hasAuthorship W2897046116A5046638351 @default.
• W2897046116 hasAuthorship W2897046116A5046639573 @default.
• W2897046116 hasAuthorship W2897046116A5057198461 @default.
• W2897046116 hasAuthorship W2897046116A5058451751 @default.
• W2897046116 hasAuthorship W2897046116A5062126812 @default.
• W2897046116 hasAuthorship W2897046116A5068096506 @default.
• W2897046116 hasAuthorship W2897046116A5075059160 @default.
• W2897046116 hasAuthorship W2897046116A5077413029 @default.
• W2897046116 hasAuthorship W2897046116A5085191511 @default.
• W2897046116 hasAuthorship W2897046116A5087850177 @default.
• W2897046116 hasConcept C121608353 @default.
• W2897046116 hasConcept C126322002 @default.
• W2897046116 hasConcept C143998085 @default.
• W2897046116 hasConcept C2776694085 @default.
• W2897046116 hasConcept C2777148230 @default.
• W2897046116 hasConcept C2778336483 @default.
• W2897046116 hasConcept C2780210213 @default.
• W2897046116 hasConcept C2780258809 @default.
• W2897046116 hasConcept C2780962732 @default.
• W2897046116 hasConcept C2781413609 @default.
• W2897046116 hasConcept C3019864225 @default.
• W2897046116 hasConcept C50382708 @default.
• W2897046116 hasConcept C526805850 @default.

• next